Benzinga | May 3, 2021 07:19AM EDT

Clearside Biomedical Announces Resubmission Of New Drug Application For XIPERE For Treatment Of Macular Edema Associated With Uveitis

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today the resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) for the treatment of macular edema associated with uveitis.